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Repurposed drugs for ALS are also of increasing interest, 
as evidenced by promising results from a phase 2 double-
blind placebo-controlled study of AMX0035.10 This com-
bination of sodium phenylbutyrate and taurur sodiol 
was designed to prevent neuronal death by simul-
taneously mitigating endoplasmic reticulum stress and 
mitochondrial dysfunction. The mean rate of decline 
in ALSFRS-R total score was significantly slower with 
AMX0035 than with placebo. A separate phase 3 study of 
taurusodiol versus placebo is underway in Europe, and it 
is likely that an additional phase 3 trial of AMX0035 will 
be initiated in 2021.
Finally, the impact of the COVID-19 pandemic on 
clinical research in ALS has been considerable. There 
has been a significant shift to remote monitoring using 
telemedicine, as reflected in numerous publications over 
the past 6 months. COVID-19 has also necessitated a 
paradigm shift for the future design and execution of 
clinical trials, with a change in emphasis from in-clinic 
evaluation to home monitoring. Home monitoring 
opens opportunities for repeated testing of defined 
outcomes over shorter periods, providing a richer data-
set of outcome measures that could, in future, reduce 
variance and improve reliability.
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Sleep research in 2020: COVID-19-related sleep disorders
2020 has been an unprecedented year because a modi-
fied coronavirus, severe acute respiratory syndrome 
corona virus 2 (SARS-CoV-2), spread rapidly from China 
to all continents, leading to the COVID-19 pandemic. 
The first studies of COVID-19-associated sleep dis orders 
were reported in China. Huang and Zhao1 collected 
information from a survey of 7236 volunteers (mean age 
35·3 years [SD 5·6]). About a third of them were health-
care workers. About 35% of these participants reported 
symptoms of general anxiety, 20% of depression, and 
18% of poor sleep quality.1 The participants who were 
most worried about the pandemic also reported the most 
symptoms. Health-care workers were clearly under great 
pressure, which was reflected in the high prevalence of 
mental-health symptoms that they reported.1
The increased prevalence of sleep dis orders in 2020 has 
also been highlighted in several other publica tions from 
different countries. These studies examined the effect on 
sleep of SARS-CoV-2 infection and confounders related 
to isolation, quarantine, anxiety, stress, or financial 
losses. According to a European task force, symptoms 
of insom nia could be related to psychosocial factors 
and to the confinements.2 In Italy, anxiety related to 
COVID-19 was highly associated with disturbed sleep. 
In a survey of 2291 Italians, 57·1% reported poor sleep 
quality, 32·1% high anxiety, 41·8% high distress, and 
7·6% reported post-traumatic symptoms of stress.3 In the 
International COVID-19 Sleep Study,4 different factors are 
being investigated using a harmonised set of questions. 
Insomnia, nightmares, sleep apnoea, fatigue, exhaustion, 
and REM sleep behaviour disorder are being investigated 
by this collaboration.4 The hypothesis is that fatigue, 
sleepiness, and REM sleep behaviour disorder might be 
related to SARS-CoV-2 infection per se, whereas insomnia 
might be related mainly to confinement, anxiety, and 
other psychosocial factors.2
Although studies related to COVID-19 have dominated 
the field in 2020, other important investigations have 
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also been published. Untreated severe sleep apnoea is 
associated with poor health and cardiovascular mor bidity 
and mortality. However, the cost-effectiveness of treating 
mild severe sleep apnoea with continuous positive 
airway pressure (CPAP) is still unclear. Two important 
randomised studies on the treatment of patients with 
severe sleep apnoea have been reported. The MERGE 
trial in the UK, which included 233 participants with mild 
untreated severe sleep apnoea (defined as having scores 
of 5–14 on the Apnoea–Hypopnoea Index [AHI]), showed 
that CPAP significantly improved quality of life (as 
measured by the Short Form Health Survey).5 Although 
this study is methodologically robust, it does not provide 
final answers, and its follow-up time was short (only 
3 months). Although 81% of the treated participants 
were willing to continue CPAP after completion of the 
trial, the improved quality of life might have been due 
to other factors. Effects of body-mass index, physical 
exercise, and sleepiness on quality of life were not 
analysed. All patients with untreated severe sleep apnoea 
should lose weight if they are obese, avoid excessive 
stress, and have a healthy lifestyle. CPAP can therefore not 
be routinely recommended for all cases of mild untreated 
severe sleep apnoea. In addition to their subjective quality 
of life, assessing daytime functioning in these patients 
is crucial.
Another large randomised study was done in Spain. 
The ISAAC study recruited 2551 individuals.6 Of the 
1264 patients without excessive daytime sleepi ness 
(Epworth Sleepiness Scale score [ESS] ≤10) and moderate-
to-severe untreated sleep apnoea (AHI scores ≥15), 
633 were randomly assigned to receive CPAP and 631 
to receive usual care. The median follow-up time was 
3·35 years. No significant differences in the occurrence 
of cardiovascular events were found. 98 (16%) of the 
events were observed in the CPAP group and 108 (17%) 
in the usual care group. The hazard ratio was 0·89 (95% CI 
0·68–1·17; p=0·40).6 Unfortunately, the investigators did 
not stratify patients with untreated severe sleep apnoea 
according to moderate (AHI scores 15–19) or severe 
(AHI scores ≥30) disease. Furthermore, they did not include 
patients with mild (ESS 11–14), moderate (ESS 15–17), or 
severe (ESS ≥18) daytime sleepiness and untreated severe 
sleep apnoea. Therefore, the results cannot be generalised 
to all patients with obstructive sleep apnoea, and certainly 
not to patients with moderate or severe (ESS >14) 
daytime sleepiness. The results indicate that CPAP might 
not be necessary in patients without excessive daytime 
sleepiness (ESS ≤10) and AHI scores of 15 or lower. The 
findings from the ISAAC and MERGE trials thus point to 
different directions. What is more important: preventing 
cardiovascular morbidity for a 3-year period or improving 
quality of life for a 3-month period? This question remains 
open. Meta-analyses and studies addressing potential 
confounders are needed.
Further important findings in sleep medicine came from 
Hablitz and colleagues,7 who showed that CSF distribution 
is under circadian control. Researchers in Copenhagen 
(Denmark) and Rochester (New York, USA) have proposed 
that interstitial ion signalling is crucial in controlling sleep 
and wakefulness.8 These investigators have also proposed 
that ion homoeostasis failure might contribute to neuro-
logical diseases and cognitive-behavioural disorders.8 
New studies done by Erlend Nagelhus and colleagues also 
show that Ca2+ signalling is essential in the regulation of 
slow wave sleep.9 All of these new studies support that 
astrocytes are key elements in the regulation of brain 
function. Emerging evidence indicates that disturbed 
sleep might be among the strongest risk factors for 
development of neurodegenerative diseases. Therefore, 
all physi cians should incorporate questions about sleep 
hygiene and quality into their routine clinical practice.
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Neurological infections in 2020: COVID-19 takes centre stage 
Although there have been many contributions to advance 
our understanding of neurological infections in 2020, 
the year has been dominated by research focused on the 
neurological consequences of COVID-19. Multidisciplin-
ary studies are ongoing to better differen tiate the direct 
effects of severe acute respiratory syn drome coronavirus 2 
(SARS-CoV-2) versus its secon dary effects (PMC7184392, 
NCT04386083, and CTRI/2020/07/026339). Neverthe-
less, it has become clear that there is a striking incidence 
of neurological involvement in this disease, the symptoms 
of which span reversible anosmia, stroke-related disability, 
and death.1–3
Dry cough, fever, dyspnoea, nausea, emesis, and fatigue 
are common symptoms of SARS-CoV-2 infection1—a 
profile shared with numerous viral infections. However, 
anosmia and ageusia, which have now been documented 
in ample research,1,2,4 are symptoms more distinctive 
of SARS-CoV-2 infection than other common viral 
infections, and the implications of these symptoms 
drive our understanding of the unique pathophysiology 
of COVID-19. In one of the largest studies to date, 
3191 individuals infected with SARS-CoV-2 were sur-
veyed to assess the prevalence of anosmia and ageusia. 
488 (15·3%) individuals were found to have one or both 
of these symptoms; in most cases, taste and smell were 
fully recovered 7 days after onset on average.1 Smaller 
studies have shown anosmia to be much more prevalent 
and the heralding symptom of SARS-CoV-2 infection,5 
therein identifying a potential source of viral replication 
and CNS invasion.
Subsequently, hypotheses emerged regard ing the 
poten tial for viral neurotropism and a direct route of 
entry into the CNS from the olfactory bulbs. In an imaging 
study6 of 23 patients with confirmed SARS-CoV-2 
infection with clinical anosmia, SARS-CoV-2-related 
olfactory dys func tion was differentiated from other 
viral olfactory dysfunction in several crucial ways. Post-
viral anosmia in the setting of upper respiratory tract 
infections is usually related to mucosal congestion and 
nasal obstruction, resulting in a conductive olfactory loss; 
however, few patients with SARS-CoV-2-related anosmia 
had sinonasal symptoms, suggesting that mucosal 
congestion is an unlikely aetiology for anosmia in these 
cases.6 Olfactory epithelium support-cells residing in 
the olfactory cleft express the angiotensin-converting 
enzyme 2 receptor, identified as the binding antigen 
for SARS-CoV-2.6 Imaging of the olfactory cleft showed 
olfactory cleft opacification in 17 (74%) of cases.6 Moving 
proxi mally, olfactory nerve filia clumping, sug gestive of 
inflammation, was observed in eight (35%) of patients, 
and olfactory bulb signal abnormalities, indicating degen-
era tion or micro haemorrhage, were seen in 21 (91%) 
individuals. Within the CNS, hyperintense T2 or fluid-
attenuated inversion recovery signals in the olfactory 
cortex were found in five (22%) individuals.
An association has been shown between SARS-
CoV-2 infection and acute inflammatory demyelinat-
ing polyradiculoneuropathy (AIDP),7 extending the viral 
pathogenic effects to the peripheral nervous system. In a 
case series of five individuals with AIDP and SARS-CoV-2 
infection, the latency between res pira tory symptom 
and neurological symptom onset was 14–30 days.7 Most 
patients presented with the classical findings of AIDP, 
with ascending paraparesis and hyporeflexia, conduc-
tion blocks and increased latency on nerve con duction 
studies, and albuminocytological dissociation in the 
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